Provided by Tiger Fintech (Singapore) Pte. Ltd.

Abeona Therapeutics

4.92
+0.08001.65%
Pre-market: 4.72-0.2000-4.07%04:19 EDT
Volume:1.21M
Turnover:5.85M
Market Cap:238.79M
PE:-3.17
High:4.99
Open:4.81
Low:4.66
Close:4.84
Loading ...

Company Profile

Company Name:
Abeona Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
136
Office Location:
6555 Carnegie Avenue,4th Floor,Cleveland,Ohio,United States
Zip Code:
44103
Fax:
- -
Introduction:
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.

Directors

Name
Position
Steven H. Rouhandeh
Chairman of the Board and Executive Chairman
Timothy J. Miller
President and Chief Executive Officer and Director
Jeffrey B. Davis
Chief Operating Officer and Director
Mark J. Alvino
Director
Stephen B. Howell
Director
Todd Wider
Director

Shareholders

Name
Position
Timothy J. Miller
President and Chief Executive Officer and Director
Jeffrey B. Davis
Chief Operating Officer and Director
Stephen B. Thompson
Vice President Finance Chief Accounting Officer, Treasurer, Secretary
Steven H. Rouhandeh
Chairman of the Board and Executive Chairman